ENCER

Company Overview

Snapshot

Founded in June 2019 by Orna Goldberg, ENCER operates with 1–10 employees. The company has raised $250,000 across one funding round. ENCER focuses on developing proprietary products to address the side effects of cancer treatment, having developed a clinically approved homeopathic solution for cancer treatment-related fatigue.

Business overview

ENCER is an emerging pharmaceutical company specializing in the research, development, and commercialization of proprietary products designed to mitigate the side effects of cancer treatment. The company's core offering is Encer+, a safe, clinically approved homeopathic solution specifically formulated to combat cancer treatment-related fatigue. This non-chemical product is designed for use in conjunction with conventional cancer treatments without causing additional side effects. ENCER operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development categories, serving patients in the healthcare industry across geomarkets including Europe and North America.

Strategic signal

ENCER's focus on homeopathic solutions for cancer treatment-related fatigue is validated by multiple research publications. A May 2021 study published in PubMed highlighted attention dysregulation in breast cancer patients following a complementary alternative treatment routine, while a June 2018 publication in PubMed explored the feasibility of homeopathic treatment for symptom reduction in an integrative oncology service. These studies indicate a growing scientific interest and potential for alternative treatments in oncology, signaling a market opportunity for ENCER's product.

Company Intelligence Q&A

What is ENCER's primary focus?

ENCER is dedicated to the research, development, and commercialization of proprietary products designed to address the side effects of cancer treatment, specifically focusing on cancer treatment-related fatigue.

When was ENCER founded?

ENCER was founded in June 2019.

What is the total capital raised by ENCER?

ENCER has raised a total of $250,000 across one funding round.

What is the status of ENCER's operations?

ENCER ceased to operate in April 2025.

Has ENCER's homeopathic treatment been studied?

Yes, a study published in PubMed in May 2021 investigated attention dysregulation in breast cancer patients following a complementary alternative treatment routine, and a June 2018 publication explored the feasibility of homeopathic treatment for symptom reduction in an integrative oncology service.